Merck Sharp + Dohme Corp.

Other

Merck Sharpe & Dohme Corp.

Merch Sharp & Dohme Ltd

Mark Peter Ridgill

Janusz Jozef Kulagowski

Andrew Madin

Neil Roy Curtis

Timothy Harrison

Paul D Leeson

Joanne Clare Hannam

Raymond Baker

Ian James Collins

Paul David Leeson

Adrian Leonard Smith

Linda Elizabeth Keown

Laura Catherine Cooper

Jose Luis Castro Pineiro

Eileen Mary Seward

Christopher Hamblett

Jed Hubbs

Ian M Mawer

Joanne Claire Hannam

Yudith Garcia

Janusz Josef Kulagowski

Alister Campbell

Sascha Hartmann

Christopher L Hamblett

Jed L Hubbs

Compounds of formula (I) are modulators of gamma-secretase, and hence are useful in treatment of Alzheimer's disease. 

Piperidines and related compounds for the treatment of Alzheimer's disease

Compounds of formula I: modulate the action of gamma secretase, and hence find use in treatment of Alzheimer's disease and related conditions. 

Piperidines and related compounds for the treatment of dementia

Compounds of formula (I) modulate the activity of gamma secretase and hence find use in treatment or prevention of Alzheimer's disease and related conditions. 

Piperidine derivatives for treatment of Alzheimer's disease

Compounds of formula I: selectively inhibit production of A&#x3b2;(1-42) and hence are useful in treatment or prevention of disease associated with deposition of &#x3b2;-amyloid in the brain.

Piperidines and related compounds for treatment of alzheimer's disease

Compounds of formula I: are potent inhibitors of gamma-secretase and hence find use in treatment or prevention of diseases associated with deposition of &#x3b2;-amyloid.

Gamma-secretase inhibitors

Compounds of formula I: inhibit the processing of AP by gamma-secretase, and hence are useful for treatment or prevention of Alzheimer's disease.

Cyclic sulfamides for inhibition of gamma-secretase

Compounds of formula (I) are disclosed: wherein Ris an alkenyl group of defined structure. The compounds inhibit gamma-secretase, and hence are useful for treatment of Alzheimer's disease. 

Alkenyl-substituted spirocyclic sulfamides as inhibitors of gamma-secretase

Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase

Compounds of formula I: inhibit the processing of APP by gamma-secretase, and hence are useful in treating or preventing Alzheimer's disease.

Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors

Compounds of formula (I) are disclosed. The compounds inhibit gamma-secretase and hence find use in treatment of Alzheimer's disease

Alkynly-substituted spirocyclic sulfamides for the treatment of alzheimer's disease

Compounds of formula I are disclosed: in which X is a 5-membered heteroaryl ring and R is as defined herein. The compounds are inhibitors of the processing of APP by gamma-secretase, and hence are useful in the treatment or prevention of Alzheimer's disease

Heteroaryl substituted spriocyclic sulfamides for inhibition of gamma secretase

A class of substituted 1,2,3,6-tetrahydropyridine derivatives are disclosed that are ligands for dopamine receptor subtypes within the body. These compounds are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia or depression.

Tetrahydropyridine derivatives as dopamine receptor subtype ligands

Tetrahydropyridinylmethyl derivatives of pyrrolo�2,3-B!pyridine

Indole derivatives as dopamine D4 antagonists

A class of pyrrolo�2,3 -b!pyridine derivatives, linked via the 3-position thereof by a methylene group to a tetrahydropyridinyl moiety, the latter moiety being substituted in turn by an aryl- or heteroaryl-substituted divalent monocyclic radical, are ligands for dopamine receptorsubtypes within the body, in particular the D.sub.4 subtype, and are accordingly of use in the treatment and/or prevention of disorders of the dopamine system, including schizophrenia and depression.

Growing community of inventors

Watton-at-Stone, United Kingdom

Mark Peter Ridgill